New York, NY – November 9, 2026 - Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, will report financial results for the third quarter 2026 ending September 30, 2026 on Thursday, November 12, 2026 after the close of the U.S. market.
The publication will be followed by an investor conference call and webcast on Friday, November 13, 2026, at 8:00 a.m. ET / 2:00 p.m. CET. The call will include the Company’s third quarter 2026 results and an update on business activities. Details for the call are as follows:
Dial in information:
Toll Free US & Canada: +1-833-354-6854
US/International Toll: +1-785-838-9343
Conference ID: CLLSQ3
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1780016&tp_key=925efa50d7